Prognostic value of three molecular forms of prostate-specific antigen ratios in patients with prostate adenocarcinoma

Urology

Volumn 57, Issue 5, 2001, Pages 936-942

  Okegawa, Takatsugu ^a,b   Kato, Moriaki ^a   Nutahara, Kikuo ^a   Higashihara, Eiji ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN ANALYSIS;

ADENOCARCINOMA; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 0035040135     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)01125-0     Document Type: Article

References (29)

1. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer; assay of the complex improves clinical sensitivity for cancer
2. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichimotrypsin
3. Prostate specific antigen predominantly forms a complex with α1-antichimotrypsin in blood
4. Prostate specific antigen; a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
5. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer
6. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications
7. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer
8. Use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer
9. Analysis of percent free prostate specific antigen for prostate cancer detection; influence of total PSA, prostate volume, and age
10. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostate disease
11. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer-studies in serum and plasma samples
12. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy; relationship to transition zone volume
13. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
14. Free-to-total prostate specific antigen ratio as a signal test for detection of significant stage T1c prostate cancer
15. The use of percent free prostate specific antigen for staging clinically localized prostate cancer
16. The free-to-total serum prostate specific antigen as a predictor of the pathological features of prostate cancer
17. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent prostate specific antigen; a prospective multicenter clinical trial
18. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer
19. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma
20. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate
21. Comparison of two investigative assays for complexed prostate-specific antigen in total prostate specific antigen between 4.1 and 10.0 ng/ml
22. Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence after radical prostatectomy
23. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer
24. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA; which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
25. A high ratio of free to total prostate specific is predominant in biochemical relapse of prostate cancer after radical prostatectomy
26. Percent free prostate-specific antigen values in men with recurrent prostate cancer after radical prostatectomy
27. Cell-cell interaction in prostate gene regulation and cytodifferentiation
28. Change in morphological and functional cytodifferentiation induced by seminal vesicle mesenchyme in cell suspensions of rat Dunning prostatic adenocarcinoma cells